Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665022 | 0.88 | DPP4 (0.33) | DPP4DPP8DPP7KCNH2CHRNB2 | |
| SCHEMBL17665163 | 0.84 | DPP4 (0.46) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL17665190 | 0.84 | DPP4 (0.46) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL21204574 | 0.84 | DPP4 (0.46) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL17665137 | 0.84 | DPP4 (0.46) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL17665188 | 0.83 | DPP4 (0.42) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL17665181 | 0.83 | DPP4 (0.42) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL21204312 | 0.82 | NPC1 (0.32) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL17665084 | 0.82 | NPC1 (0.32) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL17665212 | 0.82 | NPC1 (0.32) | DPP4DPP8DPP7CHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | DPP4 3256/4885DPP8 2354/4885DPP7 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.